Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we compared the plasma levels of NT-proBNP versus GDF-15 in patients with HF in AF versus sinus rhythm (SR).
|
31263996 |
2020 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure.
|
31663791 |
2020 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
|
31423712 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we evaluated whether GDF-15 was associated with CV death or heart failure (HF) across the spectrum of risk in non-ST-segment elevation (NSTE)-ACS.
|
30710475 |
2019 |
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to analyse the association between high-level growth-differentiation factor-15 (GDF-15) and mortality, recurrent MI and heart failure compared to low-level GDF-15 in patients with acute coronary syndrome (ACS).
|
31029521 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although, in general, effects of NRG-1 in heart failure are compensatory and beneficial, translation into therapies remains unaccomplished both because of the complexity of the underlying pathways and because of the challenges in the development of therapeutics (proteins, peptides, small molecules, and RNA-based therapies) for tyrosine kinase receptors.
|
31607147 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher NT-proBNP, hsTnT, and GDF-15 were also associated with a greater risk of HF with reduced EF; while higher NT-proBNP GDF-15 and sST2 were associated with HF with preserved EF.
|
31645163 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the setting of ACS, GDF-15 is associated with long-term all-cause death, MACE and heart failure and provides incremental prognostic value beyond traditional risks factor.
|
31369736 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease.
|
30935637 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15, a member of the transforming growth factor beta superfamily, regulates inflammatory and apoptotic pathways in various diseases, such as heart failure, kidney dysfunction, and cancer.
|
31476622 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 and left ventricular mass index (LVMI) were significantly increased as early as the pre-clinical HF stage.
|
30019695 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, clinical studies indicate that circulating, mature GDF15 is an independent biomarker for heart failure.
|
30104250 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is a promising biomarker for prediction of HF and death due to CHD in the general population, which may provide prognostic information to already established clinical biomarkers.
|
29771963 |
2018 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08-1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05-1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05-1.28, P < 0.001).
|
30204280 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In pooled analysis of both cohorts, higher levels of nine proteins were associated with incident heart failure after adjustment for established risk factors: growth differentiation factor 15 (GDF-15), T-cell immunoglobulin and mucin domain 1 (TIM-1), tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), spondin-1 (SPON1), matrix metalloproteinase-12 (MMP-12), follistatin (FS), urokinase-type plasminogen activator surface receptor (U-PAR), osteoprotegerin (OPG), and suppression of tumorigenicity 2 (ST2).
|
28967680 |
2018 |
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death.
|
30427997 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biomarkers were the strongest predictors of cause-specific death: a doubling of troponin T was most strongly associated with sudden death (hazard ratio [HR], 1.48; P<0.001), NT-proBNP with heart failure death (HR, 1.62; P<0.001), and growth differentiation factor-15 with bleeding death (HR, 1.72; P=0.028).
|
29871978 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated GDF-15 concentration was also associated with an increased rate of heart failure.
|
29866459 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In total, 232 consecutive Chinese Han patients with post-myocardial infarction CHF were enrolled prospectively from January 2014 to June 2016.The plasma concentration of GDF-15 was determined on admission and over 12 months.
|
30416510 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with HF.
|
28612904 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the prognostic impact of plasma GDF-15 and BNP in acute HF.
|
30144302 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because myocardial NRG-1/ErbB signaling has been documented to be impaired during HF associated with type 1 DM, we examined whether enhancement of NRG-1β signaling via exogenous administration of recombinant NRG-1β could exert beneficial effects against post-MI HF in the type 1 diabetic heart.
|
28870731 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism.
|
28846098 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discrimination of subjects with and without HF was slightly higher for GDF-15 (area under the ROC curve [AUC]:0.79 [95%CI:0.75-0.83]) compared to NT-proBNP (AUC:0.77 [95% CI:0.72-0.82]).
|
27838133 |
2017 |